Merck registers Phase 2/3 trial of bomedemstat versus standard therapies in polycythemia vera
The newly listed MK-3543-025 study will test bomedemstat against ruxolitinib or ropeginterferon alfa-2b in hydroxyurea-inadequate or intolerant PV patients.
Merck Sharp & Dohme posted a new registry entry for a polycythemia vera trial.
- Merck listed a Phase 2/3 trial, "MK-3543-025," testing oral bomedemstat against best available therapy, either ruxolitinib or ropeginterferon alfa-2b, in participants with polycythemia vera. Participants will receive either ropeinterferon alfa-2b or ruxolitinib as determined by investigator.1 The study is enrolling patients with an inadequate response to or intolerance to hydroxyurea.1 Eligibility further requires that patients have a history of inadequate response, resistance to, or intolerant to hydroxyurea (HU) per protocol specified criteria.1 The trial is listed as recruiting, with an estimated enrollment of 380 participants1 and treatment for up to approximately 52 weeks.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.